BridgePoint Medical was acquired by Boston Scientific in 2012. The company developed a proprietary, catheter-based system to treat coronary chronic total occlusions (CTOs). The BridgePoint Medical CTO system is comprised of the CrossBoss™ CTO Crossing Catheter and the Stingray® CTO Re-Entry System, and is designed to navigate highly diseased (occluded) coronary arteries as a means of blood flow restoration. The system received both U.S. Food and Drug Administration clearance and CE Mark.

Contact Info

13355 10th Ave. N., Suite 110, Plymouth, MN, 55441
Tel: 763-225-8500

Polaris Lead

Brian Chee

Follow on TwitterVisit our Twitter page
Social Media